Olympus Appoints Slawek Kierner as Chief Digital Officer – Smart Connected Care
Newly created role to lead digital innovation TOKYO, May 19, 2025 /PRNewswire/ -- Olympus Corporation (Olympus), a global MedTech company committed to...
Newly created role to lead digital innovation TOKYO, May 19, 2025 /PRNewswire/ -- Olympus Corporation (Olympus), a global MedTech company committed to...
ADP supports American Heart Association goal to prepare more workers to respond to cardiac emergencies DALLAS and ROSELAND, N.J., May 19,...
SAN DIEGO, May 19, 2025 /PRNewswire/ -- Cortechs.ai, a global leader in AI-driven neuroimaging solutions, today announced a strategic collaboration...
HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced...
Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move...
Seasoned biopharma executive brings more than twenty years of business development, strategy, and operational expertise to Arbor’s leadership teamCAMBRIDGE, Mass.,...
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related...
DENVER, May 19, 2025 (GLOBE NEWSWIRE) -- Porch Light Health (PLH) has partnered with CHESS Health to use its innovative,...
TOKYO, May 19, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in...
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as...
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria...
Industry veteran brings 30 years of commercial leadership experienceMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward...
Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits...
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first...
JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered...
WEST PALM BEACH, FLORIDA, May 19, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”)...
TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19,...
Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28,...
GARCHING / MUNICH, Germany and SYDNEY, May 19, 2025 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading...